![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CRIP3 |
Gene summary for CRIP3 |
![]() |
Gene information | Species | Human | Gene symbol | CRIP3 | Gene ID | 401262 |
Gene name | cysteine rich protein 3 | |
Gene Alias | CRP-3 | |
Cytomap | 6p21.1 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6Q6R5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
401262 | CRIP3 | HCC1_Meng | Human | Liver | HCC | 2.03e-06 | 2.41e-02 | 0.0246 |
401262 | CRIP3 | HCC2 | Human | Liver | HCC | 5.84e-03 | 2.46e+00 | 0.5341 |
401262 | CRIP3 | Pt13.a | Human | Liver | HCC | 1.64e-04 | 1.97e-01 | 0.021 |
401262 | CRIP3 | Pt13.b | Human | Liver | HCC | 6.96e-08 | 2.17e-01 | 0.0251 |
401262 | CRIP3 | S014 | Human | Liver | HCC | 2.74e-17 | 6.06e-01 | 0.2254 |
401262 | CRIP3 | S015 | Human | Liver | HCC | 4.10e-11 | 4.94e-01 | 0.2375 |
401262 | CRIP3 | S016 | Human | Liver | HCC | 2.19e-19 | 5.76e-01 | 0.2243 |
401262 | CRIP3 | S027 | Human | Liver | HCC | 1.69e-05 | 4.34e-01 | 0.2446 |
401262 | CRIP3 | S028 | Human | Liver | HCC | 2.36e-15 | 4.76e-01 | 0.2503 |
401262 | CRIP3 | S029 | Human | Liver | HCC | 2.55e-21 | 7.80e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Liver | Cyst | ![]() |
Lung | IAC | ![]() |
Lung | AIS | ![]() |
Lung | AAH | ![]() |
Lung | MIAC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CRIP3 | SNV | Missense_Mutation | novel | c.422G>A | p.Gly141Asp | p.G141D | Q6Q6R5 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CRIP3 | SNV | Missense_Mutation | novel | c.59C>T | p.Ser20Phe | p.S20F | Q6Q6R5 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
CRIP3 | SNV | Missense_Mutation | novel | c.283N>A | p.Phe95Ile | p.F95I | Q6Q6R5 | protein_coding | tolerated(0.39) | benign(0.293) | TCGA-AA-A01I-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CRIP3 | SNV | Missense_Mutation | c.560N>G | p.Asn187Ser | p.N187S | Q6Q6R5 | protein_coding | deleterious(0.04) | probably_damaging(0.99) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CRIP3 | SNV | Missense_Mutation | novel | c.433N>T | p.His145Tyr | p.H145Y | Q6Q6R5 | protein_coding | deleterious(0) | possibly_damaging(0.754) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CRIP3 | SNV | Missense_Mutation | rs200513888 | c.452N>A | p.Cys151Tyr | p.C151Y | Q6Q6R5 | protein_coding | deleterious(0) | possibly_damaging(0.748) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CRIP3 | SNV | Missense_Mutation | novel | c.609N>A | p.Phe203Leu | p.F203L | Q6Q6R5 | protein_coding | tolerated_low_confidence(0.2) | benign(0) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
CRIP3 | SNV | Missense_Mutation | novel | c.367N>A | p.Leu123Met | p.L123M | Q6Q6R5 | protein_coding | tolerated(0.62) | benign(0.051) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
CRIP3 | SNV | Missense_Mutation | c.69N>T | p.Lys23Asn | p.K23N | Q6Q6R5 | protein_coding | deleterious(0) | possibly_damaging(0.647) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
CRIP3 | SNV | Missense_Mutation | rs142672835 | c.457N>T | p.Arg153Cys | p.R153C | Q6Q6R5 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |